Quarterly report pursuant to Section 13 or 15(d)

Collaborative and Other Agreements - Additional Information (Details)

v3.3.0.814
Collaborative and Other Agreements - Additional Information (Details)
€ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2015
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2015
EUR (€)
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
[1]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
License and collaborative fees   $ 645,000 $ 2,450,000 $ 1,852,000   $ 4,615,000  
Deferred revenue – current $ 39,345,000 39,345,000   39,345,000     $ 1,089,000
Collaborative Arrangement | Novartis [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront payment received       37,000,000      
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       480,000,000      
Milestone received under the collaboration agreement 0            
Upfront payment included in trade and other receivables and deferred revenue current 37,000,000 37,000,000   37,000,000      
Collaborative Arrangement | Servier [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Future initial research and development expenses to be funded by counterparty       50,000,000      
License and collaborative fees   200,000 $ 600,000 1,100,000   $ 2,600,000  
Eligible milestone payments receivable | €         € 356.5    
Eligible milestone payments receivable under specific rights not met | €         633.8    
Eligible milestone payments receivable, after amendment | €         341.5    
Eligible milestone payments receivable under specific rights not met, after amendment | €         € 618.8    
Deferred revenue – current $ 1,400,000 $ 1,400,000   $ 1,400,000      
Collaborative Arrangement | Symplmed Pharmaceuticals [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Royalties receivable percentage, minimum       3.00% 3.00%    
Royalties receivable percentage, maximum       10.00% 10.00%    
[1] The condensed consolidated balance sheet as of December 31, 2014 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.